- Home
- MDAI vs IVVD Comparison
MDAI vs IVVD Comparison
Compare MDAI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- IVVD
- Stock Information
- Founded
- MDAI 2013
- IVVD 2020
- Country
- MDAI United States
- IVVD United States
- Employees
- MDAI N/A
- IVVD N/A
- Industry
- MDAI Medical/Dental Instruments
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- IVVD Health Care
- Exchange
- MDAI Nasdaq
- IVVD Nasdaq
- Market Cap
- MDAI 69.0M
- IVVD 63.4M
- IPO Year
- MDAI N/A
- IVVD 2021
- Fundamental
- Price
- MDAI $1.91
- IVVD $1.03
- Analyst Decision
- MDAI Strong Buy
- IVVD Strong Buy
- Analyst Count
- MDAI 1
- IVVD 4
- Target Price
- MDAI $3.50
- IVVD $3.64
- AVG Volume (30 Days)
- MDAI 351.9K
- IVVD 13.1M
- Earning Date
- MDAI 08-12-2025
- IVVD 08-14-2025
- Dividend Yield
- MDAI N/A
- IVVD N/A
- EPS Growth
- MDAI N/A
- IVVD N/A
- EPS
- MDAI N/A
- IVVD N/A
- Revenue
- MDAI $27,549,000.00
- IVVD $46,210,000.00
- Revenue This Year
- MDAI N/A
- IVVD $385.94
- Revenue Next Year
- MDAI $60.05
- IVVD $62.62
- P/E Ratio
- MDAI N/A
- IVVD N/A
- Revenue Growth
- MDAI 22.27
- IVVD 1941.08
- 52 Week Low
- MDAI $0.82
- IVVD $0.35
- 52 Week High
- MDAI $3.25
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- MDAI 33.85
- IVVD 63.09
- Support Level
- MDAI $1.98
- IVVD $0.77
- Resistance Level
- MDAI $2.14
- IVVD $1.14
- Average True Range (ATR)
- MDAI 0.14
- IVVD 0.13
- MACD
- MDAI -0.02
- IVVD 0.04
- Stochastic Oscillator
- MDAI 11.36
- IVVD 83.26
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.